Title(s):
Professor of Radiology and Radiological Science
Professor of Oncology
Professor of Oncology
Chief, Divison of Interventional Radiology
Director, Cardiovascular Diagnostic Laboratory
Professor of Radiology, Surgery and Oncology
Director, Cardiovascular Diagnostic Laboratory
Professor of Radiology, Surgery and Oncology
Appointment Phone:
410-614-2227
Primary Location:
The Johns Hopkins Hospital
Expertise:
Biliary Disease, Chronic Total Occlusions, Claudication, Diagnostic Radiology, Liver Disease, Lower Extremity Angioplasty, Lower Extremity Stenting, Peripheral Arterial Disease, Peripheral Vascular Disease, Renal Artery Disease, Renal Vascular Disease, Varicocele, Vascular and Interventional Radiology, Vascular Malformations, Venous Thromboembolism, Visceral Angioplasty, Visceral Stenting
Education and Experience
Training
- Boston University School of Medicine (Boston MA)/ (1991)
Residencies
- University of California San Francisco (San Francisco CA)/ Radiology (1996)
Certifications
- Diagnostic Radiology, American Board of Radiology (1998)
Locations
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-614-2648
Appointment Phone: 410-614-2227
Fax: 410-955-0233
Location Map
Johns Hopkins Outpatient Center
601 N. Caroline Street
Baltimore, MD 21287
Phone: 410-614-6597
Appointment Phone: 410-502-6611
Location Map
Department / Division
-
Radiology and Radiological Science - Vascular & Interventional Radiology
Centers/Institutes
Centers / Institutes
- Interventional Radiology Center
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
BIOGRAPHICAL SKETCH
NAME
Jean-Francois H. Geschwind POSITION TITLE
Professor Radiology, Surgery and Oncology
eRA COMMONS USER NAME (credential, e.g., agency login)
Jgeschw1
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION DEGREE
(if applicable) YEAR(s) FIELD OF STUDY
University of Paris, Paris, France B.S. 1982 Biology, Physics
University of Pennsylvania, Philadelphia, PA 1987 Biology
Boston University School of Medicine, Boston, MA M.D. 1991 Medicine
Johns Hopkins University School of Medicine, Baltimore, MD 2002 Biological Chemistry
NAME
Jean-Francois H. Geschwind POSITION TITLE
Professor Radiology, Surgery and Oncology
eRA COMMONS USER NAME (credential, e.g., agency login)
Jgeschw1
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION DEGREE
(if applicable) YEAR(s) FIELD OF STUDY
University of Paris, Paris, France B.S. 1982 Biology, Physics
University of Pennsylvania, Philadelphia, PA 1987 Biology
Boston University School of Medicine, Boston, MA M.D. 1991 Medicine
Johns Hopkins University School of Medicine, Baltimore, MD 2002 Biological Chemistry
Physician Title
Chief, Divison of Interventional Radiology
Director, Cardiovascular Diagnostic Laboratory
Professor of Radiology, Surgery and Oncology
Director, Cardiovascular Diagnostic Laboratory
Professor of Radiology, Surgery and Oncology
Awards and Honors
2001 The Dr. Ernest J. Ring Academic Development Program, SCVIR
2001 American Roentgen Ray Society Scholar
2002 Visiting Professor, Chinese University of Hong Kong
2003 Certificate of Merit, American Roentgen Ray Society
2004 Elected to AOA Honor Medical Society
2004 Elected Fellow of the Society of Interventional Radiology (FSIR)
2004 Kodak-AUR Advanced Program Radiology Management Course,
Association of University Radiologists
2005 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2006 Recognized as one of the Top Ten Radiologists in the USA by Medical Imaging Magazine
2006 Appointed to the Society of Interventional Radiology Research Foundation Board
2006 Appointed Founding Member of the International Liver Cancer Association
2007 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2007 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2007 Chairman, World Conference on Interventional Oncology 2nd Annual Meeting, Washington DC
2007 Society of Interventional Radiology Scientific Meeting Distinguished Poster Award
2010 Outstanding Faculty Award, Society of Interventional Radiology 35th Annual Scientific Meeting, 2010, Tampa, Florida
2009 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2008 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2001 American Roentgen Ray Society Scholar
2002 Visiting Professor, Chinese University of Hong Kong
2003 Certificate of Merit, American Roentgen Ray Society
2004 Elected to AOA Honor Medical Society
2004 Elected Fellow of the Society of Interventional Radiology (FSIR)
2004 Kodak-AUR Advanced Program Radiology Management Course,
Association of University Radiologists
2005 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2006 Recognized as one of the Top Ten Radiologists in the USA by Medical Imaging Magazine
2006 Appointed to the Society of Interventional Radiology Research Foundation Board
2006 Appointed Founding Member of the International Liver Cancer Association
2007 Merit Award, American Society of Clinical Oncology Gastrointestinal Cancer Symposium
2007 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2007 Chairman, World Conference on Interventional Oncology 2nd Annual Meeting, Washington DC
2007 Society of Interventional Radiology Scientific Meeting Distinguished Poster Award
2010 Outstanding Faculty Award, Society of Interventional Radiology 35th Annual Scientific Meeting, 2010, Tampa, Florida
2009 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
2008 Journal of Vascular and Interventional Radiology, Distinguished Reviewer Award
Expertise
- Biliary Disease
- Chronic Total Occlusions
- Claudication
- Diagnostic Radiology
- Liver Disease
- Lower Extremity Angioplasty
- Lower Extremity Stenting
- Peripheral Arterial Disease
- Peripheral Vascular Disease
- Renal Artery Disease
- Renal Vascular Disease
- Varicocele
- Vascular and Interventional Radiology
- Vascular Malformations
- Venous Thromboembolism
- Visceral Angioplasty
- Visceral Stenting
Professional Highlights
A. Positions and Honors.
Positions and Employment
1992-1996 Diagnostic Radiology Residency-Scholars Program
University of California - San Francisco, San Francisco, California
1996-1998 Cardiovascular and Interventional Radiology (Fellowship)
The Johns Hopkins University School of Medicine, Baltimore, Maryland
1998 Assistant Professor of Radiology and Surgery
The Johns Hopkins University School of Medicine, Baltimore, Maryland
2002 Associate Professor of Radiology, Surgery and Oncology
The Johns Hopkins University School of Medicine, Baltimore, Maryland
2002 Section Chief, Interventional Radiology
Director, Cardiovascular Diagnostic Laboratory, The Johns Hopkins Hospital,
Baltimore, Maryland
2008 Professor of Radiology, Surgery and Oncology
The Johns Hopkins University School of Medicine, Baltimore, Maryland
Positions and Employment
1992-1996 Diagnostic Radiology Residency-Scholars Program
University of California - San Francisco, San Francisco, California
1996-1998 Cardiovascular and Interventional Radiology (Fellowship)
The Johns Hopkins University School of Medicine, Baltimore, Maryland
1998 Assistant Professor of Radiology and Surgery
The Johns Hopkins University School of Medicine, Baltimore, Maryland
2002 Associate Professor of Radiology, Surgery and Oncology
The Johns Hopkins University School of Medicine, Baltimore, Maryland
2002 Section Chief, Interventional Radiology
Director, Cardiovascular Diagnostic Laboratory, The Johns Hopkins Hospital,
Baltimore, Maryland
2008 Professor of Radiology, Surgery and Oncology
The Johns Hopkins University School of Medicine, Baltimore, Maryland
Research
Research and Publications
Research Summary
Dr. Geschwind's primary research interests include finding new therapies for liver cancer, assessing tumor response after therapy using functional MR imaging, and investigating new drug delivery systems for locoregional cancer therapy. Along with colleagues from the departments of Radiology and Medicine, he has focused his research further into developing a new therapeutic approach for liver cancer using drugs specifically designed to block tumor metabolism in cancer cells.
Journal Citations Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Prieto-Ventura V, Khwaja A, Acha-Ngwodo O, Wahl RL, and Geschwind JF. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008 Jun 30.
Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, Geschwind JF, Hong K, Georgiades C, Schulick RD, Pawlik TM. Incidence and Management of Chyle Leaks Following Pancreatic Resection: A High Volume Single-Center Institutional Experience. J Gastrointest Surg. 2008 Aug 7.
Buijs M, Vossen, JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, and Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008 Oct; 249(1):346-54.
El-Khouli RH, Geschwind JF, Bluemke DA, and Kamel IR. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-71.
Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiades C, and Geschwind JF. Considerations for implantation site of Vx-2 carcinoma into rabbit liver. J Vasc Interv Radiol. 2009 Jan;20(1):113-7.
Taguchi K, Funama Y, Zhang M, Fishman EK, and Geschwind JF. Quantitative measurement of iodine concentration in the liver using abdominal C-arm computed tomography. Acad Radiol. 2009 Feb;16(2):200-8.
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, and Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-73.
Jain A, Smith C, Geschwind JF, and Pawlik TM. Image of the month: Gastrohepatic fistula following TACE for hepatocellular carcinoma. Arch Surg. 2009 Mar;144(3):285-6.
Liapi E, and Geschwind J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches. Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer. J Hepatobiliary Pancreat Surg. 2009
Ganapathy-Kanniappan S, Geschwind J.F., Kunjithapatham R, Buijs M, Vossen J, Tchernyshyov I, Cole R, Syed L, Rao P, Ota S, Vali M. Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) is Pyruvylated during 3-Bromopyruvate Mediated Cancer Cell Death. Anticancer Res. 2009 Dec;29(12):4909-4918.
Reyes DK, Vossen JA, Kamel IR, Azad N, Wahlin T, Torbenson M, Choti MA, and Geschwind JF. Single Centre Phase II Trial of Transarterial Chemoembolization with Drug Eluting Beads for Patients with Unresectable Hepatocellular Carcinoma: Initial Experience in the USA. Cancer Journal 2009 ; 15:526-532.
Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Vali M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol 2010 Jan.
Lee KH, Liapi, EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF. Doxorubicin-Loaded QuadraSphere Microspheres: Plasma Pharmacokinetics and Intratumoral Drug Concentration in an Animal Model of Liver Cancer. Cardiovasc Intervent Radio. 2010 Jan 20.
Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Geschwind JF. Embolization of Acute Nonvariceal Upper Gastrointestinal Hemorrhage Resistant to Endoscopic Treatment: Results and Predictors of Recurrent Bleeding. Cardiovasc Intervent Radiol. 2010 Mar 16.
Golzarian J, Sapoval MR, Kundu S, Hunter DW, Brountzos EN, Geschwind JF, Murphy TP, Spies JB, Wallace MJ, de Baere T, Cardella JF. Guidelines for Peripheral and Visceral Vascular Embolization Training: joing writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol. 2010 Apr; 21(4):436-41.
Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 2010 Mar;30(3):923-35.
Liapi E. and Geschwind JF. Chemoembolization for Primary and Metastatic Liver Cancer. Cancer J 2010; 16:156-162.
Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Krause D, and Geschwind JF. Packing Technique for Endovascular Coil Embolisation of Peripheral Arterial Pseudo-aneurysms with Preservation of the Parent Artery: Safety, Efficacy and Outcomes. Eur J Vasc Endovasc Surg. 2010 Apr 14.
Liapi E, and Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-46. Epub 2010 Apr 20.
Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, and Geschwind JF. 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Curr Pharm Biotechnol. 2010 Apr 26.
Kamel, I.R.; Bluemke, D.A.; Eng, J.; Liapi, E.; Messersmith, W.; Reyes, D.K.; Geschwind, J.F. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar;17(3):505-512.
Buijs, M.; Kamel, I.R.; Vossen, J.A.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug;18(8):957-963.
Dorfman, J.D.; Schulick, R.; Choti, M.A.; Geschwind, J.F.; Kamel, I.; Torbenson, M.; Thuluvath, P.J. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb 7;13(5):781-784.
Kamel, I.R.; Reyes, D.K.; Liapi, E.; Bluemke, D.A.; Geschwind, J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56.
Buijs, M.; Vossen, J.A.; Frangakis, C.; Hong, K.; Georgiades, C.S.; Chen, Y.; Liapi, E.; Geschwind, J.F. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology. 2008 Oct;249(1):346-354.
Buijs, M.; Vossen, J.A.; Hong, K.; Georgiades, C.S.; Geschwind, J.F.; Kamel, I.R. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008 Jul;191(1):285-289.
El-Khouli, R.H.; Geschwind, J.F.; Bluemke, D.A.; Kamel, I.R. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-771.
Lee, K.H.; Liapi, E.; Vossen, J.A.; Buijs, M.; Ventura, V.P.; Georgiades, C.; Hong, K.; Kamel, I.; Torbenson, M.S.; Geschwind, J.F. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008 Oct;19(10):1490-1496.
Liapi, E.; Geschwind, J.F.; Vossen, J.A.; Buijs, M.; Georgiades, C.S.; Bluemke, D.A.; Kamel, I.R. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan;190(1):67-73.
Vossen, J.A.; Buijs, M.; Syed, L.; Kutiyanwala, F.; Kutiyanwala, M.; Geschwind, J.F.; Vali, M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis. 2008;25(7):811-817.
Vossen, J.A.; Kamel, I.R.; Buijs, M.; Liapi, E.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008 May-Jun;32(3):347-352.
Yung, R.C. Epidemiology, diagnosis, staging, medical and surgical management of Lung Cancer. In: Geschwind, J.F.; Soulen, M.C., editors, Interventional Oncology: Principles and Practice; 2008.
Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009 Apr;27(2):120-123.
Hong, K.; McBride, J.D.; Georgiades, C.S.; Reyes, D.K.; Herman, J.M.; Kamel, I.R.; Geschwind, J.F. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009 Mar;20(3):360-367.
Kamel, I.R.; Liapi, E.; Reyes, D.K.; Zahurak, M.; Bluemke, D.A.; Geschwind, J.F. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-473.
Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
De Jong, M.C.; Farnell, M.B.; Sclabas, G.; Cunningham, S.C.; Cameron, J.L.; Geschwind, J.F.; Wolfgang, C.L.; Herman, J.M.; Edil, B.H.; Choti, M.A.; Schulick, R.D.; Nagorney, D.M.; Pawlik, T.M. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010 Jul;252(1):142-148.
Frangakis, C.; Geschwind, J.F.; Kim, D.; Chen, Y.; Koteish, A.; Hong, K.; Liapi, E.; Georgiades, C.S. Chemoembolization Decreases Drop-Off Risk of Hepatocellular Carcinoma Patients on the Liver Transplant List. Cardiovasc Intervent Radiol. 2010 Dec 30.
Ganapathy-Kanniappan, S.; Geschwind, J.; Kunjithapatham, R.; Buijs, M.; Syed, L.; Rao PP; Ota, S.; Vali, M. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. . Assay Drug Dev Technol 2010 2010 Apr;8(2):258-262.
Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Vali, M. 3-Bromopyruvate Induces Endoplasmic Reticulum Stress, overcomes Autophagy and causes Apoptosis in Human HCC Cell Lines. Anticancer Res. 2010 Mar;30(3):923-935.
Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Vali, M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes with the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258-262.
Ganapathy-Kanniappan, S.; Vali, M.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Geschwind, J.F. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510-517.
Hong, K.; Geschwind, J.F. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 2010 Apr;37(2):110-117.
Lee, K.H.; Liapi, E.A.; Cornell, C.; Reb, P.; Buijs, M.; Vossen, J.A.; Ventura, V.P.; Geschwind, J.F. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol. 2010 Jun;33(3):576-582.
Liapi, E.; Geschwind, J. Chemoembolization for primary and metastatic liver cancer. . Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
Liapi, E.; Geschwind, J. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? . Ann Surg Oncol 2010;17(5):1234-1246.
Liapi, E.; Geschwind, J.F. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
Liapi, E.; Geschwind, J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-406.
Liapi, E.; Geschwind, J.F. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-1246.
Lin, M.; Loffroy, R.; Noordhoek, N.; Taguchi, K.; Radaelli, A.; Blijd, J.; Balguid, A.; Geschwind, J.F. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minim Invasive Ther Allied Technol. 2010 Nov 17;Epub Nov. 17.
Loffroy, R.; Gergele, F.; Rao, P.; Geschwind, J.F. Endovascular management of a posttraumatic pseudoaneurysm of the common carotid artery with superselective coil embolization. J Vasc Surg. 2010 May 25;Epub May, 2010.
Loffroy, R.; Rao, P.; Kwak, B.K.; Ota, S.; De Lin, M.; Liapi, E.; Geschwind, J.F. Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol. 2010 May-Jun;11(3):257-268.
Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Geschwind, J.F. Embolization of acute nonvariceal upper gastrointestinal hemorrhage resistant to endoscopic treatment: results and predictors of recurrent bleeding. Cardiovasc Intervent Radiol. 2010 Dec;33(6):1088-1100.
Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Krause, D.; Geschwind, J.F. Packing technique for endovascular coil embolisation of peripheral arterial pseudo-aneurysms with preservation of the parent artery: safety, efficacy and outcomes. Eur J Vasc Endovasc Surg. 2010 Aug;40(2):209-215.
Loffroy, R.; Rao, P.; Ota, S.; Geschwind, J.F. Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol. 2010 Jul;83(991):630; author reply 631-632.
Schwarz, R.E.; Abou-Alfa, G.K.; Geschwind, J.F.; Krishnan, S.; Salem, R.; Venook, A.P. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun;12(5):313-320.
Golzarian, J.; Sapoval, M.; Kundu, S.; Hunter, D.; Brountzo, E.; Geschwind, J.; Murphy, T.; Spies, J.; Wallace, M.; de Baere, T.; Cardella, J. Guidelines for Peripheral and Visceral Vascular Embolization Training: joint writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol 2010 2010 Apr;21(4):436-441.
Liapi, E.; Geschwind, J.F. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49.
Liapi, E.; JF, H.G.; Vali, M.; Khwaja, A.A.; Prieto-Ventura, V.; Buijs, M.; Vossen, J.A.; Ganapathy, S.; Wahl, R.L. Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med. 2011 Feb;52(2):225-230.
Dr. Geschwind's primary research interests include finding new therapies for liver cancer, assessing tumor response after therapy using functional MR imaging, and investigating new drug delivery systems for locoregional cancer therapy. Along with colleagues from the departments of Radiology and Medicine, he has focused his research further into developing a new therapeutic approach for liver cancer using drugs specifically designed to block tumor metabolism in cancer cells.
Journal Citations Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Prieto-Ventura V, Khwaja A, Acha-Ngwodo O, Wahl RL, and Geschwind JF. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008 Jun 30.
Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, Geschwind JF, Hong K, Georgiades C, Schulick RD, Pawlik TM. Incidence and Management of Chyle Leaks Following Pancreatic Resection: A High Volume Single-Center Institutional Experience. J Gastrointest Surg. 2008 Aug 7.
Buijs M, Vossen, JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, and Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008 Oct; 249(1):346-54.
El-Khouli RH, Geschwind JF, Bluemke DA, and Kamel IR. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-71.
Lee KH, Liapi E, Buijs M, Vossen J, Hong K, Georgiades C, and Geschwind JF. Considerations for implantation site of Vx-2 carcinoma into rabbit liver. J Vasc Interv Radiol. 2009 Jan;20(1):113-7.
Taguchi K, Funama Y, Zhang M, Fishman EK, and Geschwind JF. Quantitative measurement of iodine concentration in the liver using abdominal C-arm computed tomography. Acad Radiol. 2009 Feb;16(2):200-8.
Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, and Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-73.
Jain A, Smith C, Geschwind JF, and Pawlik TM. Image of the month: Gastrohepatic fistula following TACE for hepatocellular carcinoma. Arch Surg. 2009 Mar;144(3):285-6.
Liapi E, and Geschwind J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches. Targeting tumor metabolism via a loco-regional approach: A new therapy against liver cancer. J Hepatobiliary Pancreat Surg. 2009
Ganapathy-Kanniappan S, Geschwind J.F., Kunjithapatham R, Buijs M, Vossen J, Tchernyshyov I, Cole R, Syed L, Rao P, Ota S, Vali M. Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) is Pyruvylated during 3-Bromopyruvate Mediated Cancer Cell Death. Anticancer Res. 2009 Dec;29(12):4909-4918.
Reyes DK, Vossen JA, Kamel IR, Azad N, Wahlin T, Torbenson M, Choti MA, and Geschwind JF. Single Centre Phase II Trial of Transarterial Chemoembolization with Drug Eluting Beads for Patients with Unresectable Hepatocellular Carcinoma: Initial Experience in the USA. Cancer Journal 2009 ; 15:526-532.
Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Vali M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes With the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol 2010 Jan.
Lee KH, Liapi, EA, Cornell C, Reb P, Buijs M, Vossen JA, Ventura VP, Geschwind JF. Doxorubicin-Loaded QuadraSphere Microspheres: Plasma Pharmacokinetics and Intratumoral Drug Concentration in an Animal Model of Liver Cancer. Cardiovasc Intervent Radio. 2010 Jan 20.
Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Geschwind JF. Embolization of Acute Nonvariceal Upper Gastrointestinal Hemorrhage Resistant to Endoscopic Treatment: Results and Predictors of Recurrent Bleeding. Cardiovasc Intervent Radiol. 2010 Mar 16.
Golzarian J, Sapoval MR, Kundu S, Hunter DW, Brountzos EN, Geschwind JF, Murphy TP, Spies JB, Wallace MJ, de Baere T, Cardella JF. Guidelines for Peripheral and Visceral Vascular Embolization Training: joing writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol. 2010 Apr; 21(4):436-41.
Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 2010 Mar;30(3):923-35.
Liapi E. and Geschwind JF. Chemoembolization for Primary and Metastatic Liver Cancer. Cancer J 2010; 16:156-162.
Loffroy R, Rao P, Ota S, De Lin M, Kwak BK, Krause D, and Geschwind JF. Packing Technique for Endovascular Coil Embolisation of Peripheral Arterial Pseudo-aneurysms with Preservation of the Parent Artery: Safety, Efficacy and Outcomes. Eur J Vasc Endovasc Surg. 2010 Apr 14.
Liapi E, and Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-46. Epub 2010 Apr 20.
Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, and Geschwind JF. 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy. Curr Pharm Biotechnol. 2010 Apr 26.
Kamel, I.R.; Bluemke, D.A.; Eng, J.; Liapi, E.; Messersmith, W.; Reyes, D.K.; Geschwind, J.F. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar;17(3):505-512.
Buijs, M.; Kamel, I.R.; Vossen, J.A.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug;18(8):957-963.
Dorfman, J.D.; Schulick, R.; Choti, M.A.; Geschwind, J.F.; Kamel, I.; Torbenson, M.; Thuluvath, P.J. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb 7;13(5):781-784.
Kamel, I.R.; Reyes, D.K.; Liapi, E.; Bluemke, D.A.; Geschwind, J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56.
Buijs, M.; Vossen, J.A.; Frangakis, C.; Hong, K.; Georgiades, C.S.; Chen, Y.; Liapi, E.; Geschwind, J.F. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology. 2008 Oct;249(1):346-354.
Buijs, M.; Vossen, J.A.; Hong, K.; Georgiades, C.S.; Geschwind, J.F.; Kamel, I.R. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008 Jul;191(1):285-289.
El-Khouli, R.H.; Geschwind, J.F.; Bluemke, D.A.; Kamel, I.R. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct;32(5):769-771.
Lee, K.H.; Liapi, E.; Vossen, J.A.; Buijs, M.; Ventura, V.P.; Georgiades, C.; Hong, K.; Kamel, I.; Torbenson, M.S.; Geschwind, J.F. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008 Oct;19(10):1490-1496.
Liapi, E.; Geschwind, J.F.; Vossen, J.A.; Buijs, M.; Georgiades, C.S.; Bluemke, D.A.; Kamel, I.R. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan;190(1):67-73.
Vossen, J.A.; Buijs, M.; Syed, L.; Kutiyanwala, F.; Kutiyanwala, M.; Geschwind, J.F.; Vali, M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis. 2008;25(7):811-817.
Vossen, J.A.; Kamel, I.R.; Buijs, M.; Liapi, E.; Georgiades, C.S.; Hong, K.; Geschwind, J.F. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008 May-Jun;32(3):347-352.
Yung, R.C. Epidemiology, diagnosis, staging, medical and surgical management of Lung Cancer. In: Geschwind, J.F.; Soulen, M.C., editors, Interventional Oncology: Principles and Practice; 2008.
Buijs, M.; Vossen, J.A.; Geschwind, J.F.; Ishimori, T.; Engles, J.M.; Acha-Ngwodo, O.; Wahl, R.L.; Vali, M. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs. 2009 Apr;27(2):120-123.
Hong, K.; McBride, J.D.; Georgiades, C.S.; Reyes, D.K.; Herman, J.M.; Kamel, I.R.; Geschwind, J.F. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009 Mar;20(3):360-367.
Kamel, I.R.; Liapi, E.; Reyes, D.K.; Zahurak, M.; Bluemke, D.A.; Geschwind, J.F. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb;250(2):466-473.
Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
Reyes, D.K.; Vossen, J.A.; Kamel, I.R.; Azad, N.S.; Wahlin, T.A.; Torbenson, M.S.; Choti, M.A.; Geschwind, J.F. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec;15(6):526-532.
De Jong, M.C.; Farnell, M.B.; Sclabas, G.; Cunningham, S.C.; Cameron, J.L.; Geschwind, J.F.; Wolfgang, C.L.; Herman, J.M.; Edil, B.H.; Choti, M.A.; Schulick, R.D.; Nagorney, D.M.; Pawlik, T.M. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010 Jul;252(1):142-148.
Frangakis, C.; Geschwind, J.F.; Kim, D.; Chen, Y.; Koteish, A.; Hong, K.; Liapi, E.; Georgiades, C.S. Chemoembolization Decreases Drop-Off Risk of Hepatocellular Carcinoma Patients on the Liver Transplant List. Cardiovasc Intervent Radiol. 2010 Dec 30.
Ganapathy-Kanniappan, S.; Geschwind, J.; Kunjithapatham, R.; Buijs, M.; Syed, L.; Rao PP; Ota, S.; Vali, M. The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. . Assay Drug Dev Technol 2010 2010 Apr;8(2):258-262.
Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Vali, M. 3-Bromopyruvate Induces Endoplasmic Reticulum Stress, overcomes Autophagy and causes Apoptosis in Human HCC Cell Lines. Anticancer Res. 2010 Mar;30(3):923-935.
Ganapathy-Kanniappan, S.; Geschwind, J.F.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Vali, M. The Pyruvic Acid Analog 3-Bromopyruvate Interferes with the Tetrazolium Reagent MTS in the Evaluation of Cytotoxicity. Assay Drug Dev Technol. 2010 Apr;8(2):258-262.
Ganapathy-Kanniappan, S.; Vali, M.; Kunjithapatham, R.; Buijs, M.; Syed, L.H.; Rao, P.P.; Ota, S.; Kwak, B.K.; Loffroy, R.; Geschwind, J.F. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol. 2010 Aug;11(5):510-517.
Hong, K.; Geschwind, J.F. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 2010 Apr;37(2):110-117.
Lee, K.H.; Liapi, E.A.; Cornell, C.; Reb, P.; Buijs, M.; Vossen, J.A.; Ventura, V.P.; Geschwind, J.F. Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol. 2010 Jun;33(3):576-582.
Liapi, E.; Geschwind, J. Chemoembolization for primary and metastatic liver cancer. . Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
Liapi, E.; Geschwind, J. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? . Ann Surg Oncol 2010;17(5):1234-1246.
Liapi, E.; Geschwind, J.F. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010 2010 Mar-Apr;16(2):156-162.
Liapi, E.; Geschwind, J.F. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-406.
Liapi, E.; Geschwind, J.F. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010 May;17(5):1234-1246.
Lin, M.; Loffroy, R.; Noordhoek, N.; Taguchi, K.; Radaelli, A.; Blijd, J.; Balguid, A.; Geschwind, J.F. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minim Invasive Ther Allied Technol. 2010 Nov 17;Epub Nov. 17.
Loffroy, R.; Gergele, F.; Rao, P.; Geschwind, J.F. Endovascular management of a posttraumatic pseudoaneurysm of the common carotid artery with superselective coil embolization. J Vasc Surg. 2010 May 25;Epub May, 2010.
Loffroy, R.; Rao, P.; Kwak, B.K.; Ota, S.; De Lin, M.; Liapi, E.; Geschwind, J.F. Transcatheter arterial embolization in patients with kidney diseases: an overview of the technical aspects and clinical indications. Korean J Radiol. 2010 May-Jun;11(3):257-268.
Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Geschwind, J.F. Embolization of acute nonvariceal upper gastrointestinal hemorrhage resistant to endoscopic treatment: results and predictors of recurrent bleeding. Cardiovasc Intervent Radiol. 2010 Dec;33(6):1088-1100.
Loffroy, R.; Rao, P.; Ota, S.; De Lin, M.; Kwak, B.K.; Krause, D.; Geschwind, J.F. Packing technique for endovascular coil embolisation of peripheral arterial pseudo-aneurysms with preservation of the parent artery: safety, efficacy and outcomes. Eur J Vasc Endovasc Surg. 2010 Aug;40(2):209-215.
Loffroy, R.; Rao, P.; Ota, S.; Geschwind, J.F. Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol. 2010 Jul;83(991):630; author reply 631-632.
Schwarz, R.E.; Abou-Alfa, G.K.; Geschwind, J.F.; Krishnan, S.; Salem, R.; Venook, A.P. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010 Jun;12(5):313-320.
Golzarian, J.; Sapoval, M.; Kundu, S.; Hunter, D.; Brountzo, E.; Geschwind, J.; Murphy, T.; Spies, J.; Wallace, M.; de Baere, T.; Cardella, J. Guidelines for Peripheral and Visceral Vascular Embolization Training: joint writing groups of the Standards of Practice Committees for the Society of Interventional Radiology (SIR), Cardiovascular and Interventional Radiological Society of Europe (CIRSE), and Canadian Interventional Radiology Association (CIRA). J Vasc Interv Radiol 2010 2010 Apr;21(4):436-441.
Liapi, E.; Geschwind, J.F. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol. 2011 Feb;34(1):37-49.
Liapi, E.; JF, H.G.; Vali, M.; Khwaja, A.A.; Prieto-Ventura, V.; Buijs, M.; Vossen, J.A.; Ganapathy, S.; Wahl, R.L. Assessment of Tumoricidal Efficacy and Response to Treatment with 18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor. J Nucl Med. 2011 Feb;52(2):225-230.
Research Interests
- Liver cancer
More Info
Languages
- English
- French
Memberships
PROFESSIONAL SOCIETIES:
Eastern Cooperative Oncology Group
American Society of Clinical Oncology
American Roentgen Ray Society
American Association for Cancer Research
Association of University Radiologists
Cardiovascular and Interventional Society of Europe
Society of Interventional Radiology
Radiology Society of North America
Association of California Interns and Residents
California Medical Association
Chesapeake Interventional Radiology Society
Eastern Cooperative Oncology Group
American Society of Clinical Oncology
American Roentgen Ray Society
American Association for Cancer Research
Association of University Radiologists
Cardiovascular and Interventional Society of Europe
Society of Interventional Radiology
Radiology Society of North America
Association of California Interns and Residents
California Medical Association
Chesapeake Interventional Radiology Society
Clinical Trials
- Interventional oncology
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts